Ena Segota, MD Taussig Cancer Center, The Cleveland Clinic Foundation
Ronald M. Bukowski, MD Director of Experimental Therapeutics Program, Taussig Cancer Center, The Cleveland Clinic Foundation
Address: Ronald M. Bukowski, MD, Taussig Cancer Center, R33, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
Dr. Bukowski has indicated that he has received grant or research support from the Wyeth, Human Genome Sciences, Bristol-Myers Squibb, and Novartis corporations, is a consultant for Novartis and Celgene, and is on the speaker’s bureau of Schering, Cheron, and Celgene.
This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.
ABSTRACTToxic chemotherapeutic agents are slowly being supplemented by a new generation of drugs that recognize specific targets in or on cancer cells. Although these molecular and genetic approaches are in their infancy, they hold the promise of more effective therapies with markedly fewer side effects. Several targeted agents are already approved by the US Food and Drug Administration (FDA) for use in malignancies, and numerous others are in clinical trials.
